Back to Search Start Over

Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS

Authors :
Gianfranco Umberto Meduri
George P. Chrousos
Dijillali Annane
Barbara Ruaro
Bernd Meibohm
Bram Rochwerg
Amanda Busby
Marco Confalonieri
The University of Tennessee Health Science Center [Memphis] (UTHSC)
Infection et inflammation (2I)
Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)
University of Trieste
University of Athens Medical School [Athens]
McMaster University [Hamilton, Ontario]
University of Hertfordshire [Hatfield] (UH)
The authors thank Professor William J. Jusko, PhD, University at Buffalo School of Pharmacy and Pharmaceutical Sciences for critical review of the manuscript and Barbara Wade for her linguistic advice.
Gianfranco Umberto Meduri
Djillali, Annane
Confalonieri, Marco
Chrousos, George P.
Bram, Rochwerg
Amanda, Busby
Barbara Ruaro &amp
Bernd, Meibohm
Ruaro, Barbara
Source :
Intensive Care Medicine, Intensive Care Medicine, Springer Verlag, 2020, 46 (12), pp.2284-2296. ⟨10.1007/s00134-020-06289-8⟩
Publication Year :
2020
Publisher :
HAL CCSD, 2020.

Abstract

Current literature addressing the pharmacological principles guiding glucocorticoid (GC) administration in ARDS is scant. This paucity of information may have led to the heterogeneity of treatment protocols and misinterpretation of available findings. GCs are agonist compounds that bind to the GC receptor (GR) producing a pharmacological response. Clinical efficacy depends on the magnitude and duration of exposure to GR. We updated the meta-analysis of randomized trials investigating GC treatment in ARDS, focusing on treatment protocols and response. We synthesized the current literature on the role of the GR in GC therapy including genomic and non-genomic effects, and integrated current clinical pharmacology knowledge of various GCs, including hydrocortisone, methylprednisolone and dexamethasone. This review addresses the role dosage, timing of initiation, mode of administration, duration, and tapering play in achieving optimal response to GC therapy in ARDS. Based on RCTs’ findings, GC plasma concentration–time profiles, and pharmacodynamic studies, optimal results are most likely achievable with early intervention, an initial bolus dose to achieve close to maximal GRα saturation, followed by a continuous infusion to maintain high levels of response throughout the treatment period. In addition, patients receiving similar GC doses may experience substantial between-patient variability in plasma concentrations affecting clinical response. GC should be dose-adjusted and administered for a duration targeting clinical and laboratory improvement, followed by dose-tapering to achieve gradual recovery of the suppressed hypothalamic–pituitary–adrenal (HPA) axis. These findings have practical clinical relevance. Future RCTs should consider these pharmacological principles in the study design and interpretation of findings. Electronic supplementary material The online version of this article (10.1007/s00134-020-06289-8) contains supplementary material, which is available to authorized users.

Details

Language :
English
ISSN :
03424642 and 14321238
Database :
OpenAIRE
Journal :
Intensive Care Medicine, Intensive Care Medicine, Springer Verlag, 2020, 46 (12), pp.2284-2296. ⟨10.1007/s00134-020-06289-8⟩
Accession number :
edsair.doi.dedup.....df00736ac30b88ba764ea46abc2bc40a
Full Text :
https://doi.org/10.1007/s00134-020-06289-8⟩